KIR2DL2，全稱為殺傷細(xì)胞免疫球蛋白樣受體2DL2，也被稱為NKAT6、p58.2、CD158b1。該蛋白是一種跨膜糖蛋白，屬于殺傷細(xì)胞免疫球蛋白樣受體（KIR）家族。KIR2DL2主要表達(dá)在自然殺傷（NK）細(xì)胞和部分T細(xì)胞上，通過識(shí)別HLA-C類分子來(lái)調(diào)節(jié)NK細(xì)胞的活化和抑制。它能夠抑制NK細(xì)胞的細(xì)胞毒性作用，從而防止正常細(xì)胞被錯(cuò)誤地攻擊。KIR2DL2與多種疾病相關(guān)，包括癌癥、自身免疫性疾病等。在藥物研發(fā)方面，針對(duì)KIR2DL2的抗體已被開發(fā)出來(lái)，用于治療某些癌癥和自身免疫性疾病。

熱銷產(chǎn)品

KIR2DL2 Antibody (CSB-PA012353LA01HU)

驗(yàn)證數(shù)據(jù)

Immunofluorescence staining of A549 cells with CSB-PA012353LA01HU at 1:133, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).